Vistagen Appoints Cindy Anderson as Chief Financial Officer
22 Agosto 2023 - 2:30PM
Business Wire
Anderson succeeds Jerrold Dotson who is
retiring after a distinguished decade-long career with Vistagen
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical
company aiming to transform the treatment landscape for individuals
living with anxiety, depression and other central nervous system
(CNS) disorders, today announced the appointment of Cindy Anderson
as Chief Financial Officer (CFO), effective August 21, 2023. Ms.
Anderson will succeed Jerrold Dotson, whose planned retirement was
announced in July of this year.
“We are delighted to welcome Ms. Anderson, an experienced and
highly accomplished finance professional, to our team,” said Shawn
Singh, Chief Executive Officer of Vistagen. “As CFO, Ms. Anderson
will leverage deep experience in corporate strategic and financial
operations while managing finance and growth objectives as we work
to bring novel CNS treatments to patients. On behalf of Vistagen,
I’d like to express our sincere gratitude to Mr. Dotson for his
dedicated service and invaluable contributions to the company
during his remarkable tenure. As he embarks on his retirement, we
extend our best wishes for success and fulfillment in the future.
At the same time, we remain steadfast in our work to advance our
mission and enthusiastically welcome Ms. Anderson to our
accomplished team."
Ms. Anderson brings almost two decades of financial and
operating strength from her experiences in the biotechnology
sector. She joins Vistagen from Alnylam Pharmaceuticals where she
served as the Chief Accounting Officer, focused on strategic and
financial operations. Prior to Alnylam, she served in various roles
of increasing responsibility at Alexion Pharmaceuticals and at
Ernst & Young. Ms. Anderson began her career at
PricewaterhouseCoopers and is a certified public accountant. Ms.
Anderson holds a B.S. in Business Administration from the
University of Connecticut and a M.S. in Accounting from the
University of Texas at Dallas. She earned her CPA in Texas.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage
biopharmaceutical company aiming to transform the treatment
landscape for individuals living with anxiety, depression and other
CNS disorders. Vistagen is advancing therapeutics with the
potential to be faster-acting, and with fewer side effects and
safety concerns, than those currently available for the treatment
of anxiety, depression and multiple CNS disorders. Vistagen's
pipeline includes six clinical-stage product candidates, including
fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an
investigational agent belonging to a new class of drugs known as
pherines, as well as AV-101, which is an oral prodrug of an
antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines
are neuroactive nasal sprays designed with an innovative proposed
mechanism of action that activates chemosensory neurons in the
nasal cavity and can beneficially impact key neural circuits in the
brain without systemic absorption or direct activity on neurons in
the brain. Vistagen is passionate about transforming mental health
care and redefining what is possible in the treatment of anxiety,
depression and several other CNS disorders. Connect at
www.Vistagen.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the federal securities laws. These
forward-looking statements involve known and unknown risks that are
difficult to predict and include all matters that are not
historical facts. In some cases, you can identify forward-looking
statements by the use of words such as “may,” “could,” “expect,”
“project,” “outlook,” “strategy,” “intend,” “plan,” “seek,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“strive,” “goal,” “continue,” “likely,” “will,” “would” and
variations of these terms and similar expressions, or the negative
of these terms or similar expressions. Such forward-looking
statements are necessarily based upon estimates and assumptions
that, while considered reasonable by Vistagen and its management,
are inherently uncertain. These risks and uncertainties are fully
discussed in the section entitled "Risk Factors" in our most recent
Annual Report on Form 10-K for the year ended March 31, 2023, and
in our most recent Quarterly Report on Form 10-Q for the quarter
ended June 30, 2023, as well as discussions of potential risks,
uncertainties, and other important factors in our other filings
with the U.S. Securities and Exchange Commission (SEC). Our SEC
filings are available on the SEC’s website at www.sec.gov. In
addition, any forward-looking statements represent our views only
as of the issuance of this release and should not be relied upon as
representing our views as of any subsequent date. We explicitly
disclaim any obligation to update any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230822149790/en/
Investors Mark McPartland Senior Vice President, Investor
Relations (650) 577-3606 markmcp@vistagen.com
Media Nate Hitchings SKDK nhitchings@skdknick.com
Grafico Azioni Vistagen Therapeutics (NASDAQ:VTGN)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Vistagen Therapeutics (NASDAQ:VTGN)
Storico
Da Mag 2023 a Mag 2024